Eli Lilly and Company operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Eli Lilly and Company with three other
companies in this sector in UNITED STATES :
Bristol-Myers Squibb Company
(2019
sales of $26.15 billion
of which 30%
was Prioritized Brands-Eliquis),
Takeda Pharmaceutical Company Limited
($18.90 billion
of which 97%
was Pharmaceutical Business), and
AstraZeneca PLC
($24.38 billion
of which 100%
was BioPharmaceuticals).
Sales Analysis.
Eli Lilly and Company reported sales of $22.32 billion
for the
year ending
December of 2019.
This
represents
a
decrease of 9.1%
versus 2018, when the company's sales were $24.56 billion.